[
  {
    "ts": null,
    "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=ede6346b2f0def6b1eb1cfeceb2966284b3b1ede5f915c314a631c371ddab371",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759854660,
      "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "id": 137007178,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=ede6346b2f0def6b1eb1cfeceb2966284b3b1ede5f915c314a631c371ddab371"
    }
  },
  {
    "ts": null,
    "headline": "Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 Billion by 2033 as Gene Therapies and RNA-based Treatments Redefine Patient Outcomes",
    "summary": "The Neuromuscular Disease Therapeutics Market is entering a period of accelerated growth, supported by breakthroughs in gene therapy, antisense oligonucleotides (ASOs), monoclonal antibodies, and small-molecule modulators. According to DataM Intelligence, the Neuromuscular Disease Therapeutics Market Size reached US$ 11.89 billion in 2023, rose to US$ 13.70 billion in 2024, and is projected to reach US$ 45.62 billion by 2033, growing at a CAGR of 14.4% during 2025–2033.",
    "url": "https://finnhub.io/api/news?id=9ca05e134f35b94c3ed25a19fb6a0ca3e0477aee5fb8d0a79f0c9e229d8b6e55",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759850400,
      "headline": "Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 Billion by 2033 as Gene Therapies and RNA-based Treatments Redefine Patient Outcomes",
      "id": 136998885,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The Neuromuscular Disease Therapeutics Market is entering a period of accelerated growth, supported by breakthroughs in gene therapy, antisense oligonucleotides (ASOs), monoclonal antibodies, and small-molecule modulators. According to DataM Intelligence, the Neuromuscular Disease Therapeutics Market Size reached US$ 11.89 billion in 2023, rose to US$ 13.70 billion in 2024, and is projected to reach US$ 45.62 billion by 2033, growing at a CAGR of 14.4% during 2025–2033.",
      "url": "https://finnhub.io/api/news?id=9ca05e134f35b94c3ed25a19fb6a0ca3e0477aee5fb8d0a79f0c9e229d8b6e55"
    }
  },
  {
    "ts": null,
    "headline": "Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?",
    "summary": "MRK's stock witnesses an upside after Pfizer's pricing deal, but Gardasil's slump and Keytruda's looming LOE keep investors cautious.",
    "url": "https://finnhub.io/api/news?id=1abb297e6be03716f7053f6b96fee93e78e971ceb9e28854be00a15c20572caa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759840020,
      "headline": "Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?",
      "id": 136998886,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "MRK's stock witnesses an upside after Pfizer's pricing deal, but Gardasil's slump and Keytruda's looming LOE keep investors cautious.",
      "url": "https://finnhub.io/api/news?id=1abb297e6be03716f7053f6b96fee93e78e971ceb9e28854be00a15c20572caa"
    }
  },
  {
    "ts": null,
    "headline": "3 Dividend Stocks to Double Up On Right Now",
    "summary": "The time is right for buying more of these great dividend stocks.",
    "url": "https://finnhub.io/api/news?id=bc892e5ed3a8656c2ad82c0c11836ea3a2df1e8034124cc294bcf8e6ddf67e9b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759826640,
      "headline": "3 Dividend Stocks to Double Up On Right Now",
      "id": 136998887,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The time is right for buying more of these great dividend stocks.",
      "url": "https://finnhub.io/api/news?id=bc892e5ed3a8656c2ad82c0c11836ea3a2df1e8034124cc294bcf8e6ddf67e9b"
    }
  }
]